Has the EU Incentive for Drug Repositioning Been Effective? An Empirical Analysis of the “+1” Regulatory Exclusivity

Author:

Liddicoat Johnathon,Liddell Kathleen,Aboy Mateo,Wested Jakob

Abstract

AbstractEU law incentivises drug marketing authorisation holders (MAHs) to find new uses for their compounds (research known as “repositioning”) by offering them an extra year of market protection if the new use is authorised. This extra year, known as the “+1”, was enacted on limited evidence, and no study has examined its effect since it began. Yet, several leading commentators suggest lengthening the +1. This study assesses the effectiveness of the +1 by analysing all the relevant instances of MAHs repositioning their drugs before and after the +1 came into effect. The results show that: (i) 42.2% of MAHs repositioned their drugs before the +1 came into effect, and (ii) once the +1 did come into effect, it did not increase the percentage of MAHs that repositioned their drugs. This study finds that the +1 failed to increase repositioning and then proceeds to consider reform options, including repealing the law. In doing so, this study takes the first steps towards an evidence-based policy for the topic.

Funder

University of Cambridge

Publisher

Springer Science and Business Media LLC

Subject

Law,Political Science and International Relations

Reference72 articles.

1. Ackermann M (2020) No need for “plausibility” in German patent law. GRUR Int 70(1):3–10

2. Allergan Inc et al (2011) Brief of amici curia Allergan Inc, Shire Pharmaceuticals Inc, Medicis Pharmaceutical Corp and Somaxon Corp in support of the respondents. Caraco Pharmaceutical Laboratories Ltd v Novo Nordisk A/S, 566 US 399 (2012)

3. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673–683

4. Balogh S (2016) Extensions of indication in the European Union—a regulatory overview. Master’s thesis, Bonn, pp i–112. https://dgra.de/media/pdf/studium/masterthesis/master_balogh_s.pdf. Accessed 10 Dec 2020

5. Beall RF, Kesselheim AS (2018) Tertiary patenting on drug-device combination products in the United States. Nat Biotechnol 36(2):142–145

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Repositioning Generic Drugs: Empirical Findings and Policy Implications;IIC - International Review of Intellectual Property and Competition Law;2022-09-12

2. Mapping the European patent landscape for medical uses of known products;Nature Biotechnology;2021-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3